Novo Nordisk (NOVA) Price & Analysis

Compare

130 Followers

NOVA Stock Chart & Stats

Day’s Range― - ―

52-Week Range€38.20 - €124.50

Previous CloseN/A

Volume1.40K

Average Volume (3M)6.82K

Market Cap

$208.09B

Enterprise Value€319.55B

Total Cash (Recent Filing)$18.93B

Total Debt (Recent Filing)$99.27B

Price to Earnings (P/E)14.1

Beta0.70

Next Earnings

Nov 05, 2025

EPS Estimate

0.8

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.79

Shares Outstanding3,390,128,000

10 Day Avg. Volume3,027

30 Day Avg. Volume6,823

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.54

Enterprise Value/Revenue1.02

Enterprise Value/Gross Profit1.22

Enterprise Value/Ebitda1.87

Forecast

1Y Price Target

$57.81

Price Target Upside25.39% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering8

Bulls Say, Bears Say

Bulls Say

Market OpportunityUntapped segment of the obesity market could be unlocked by an oral formulation.

Product DevelopmentManagement is excited by the oral sema obesity opportunity which should benefit from a bolstered cash pay option.

Regulatory ApprovalWegovy's approval in MASH marks a small win in what has been a more difficult year for Novo shares.

Bears Say

Financial PerformanceThe second guidance cut a focus of investor concerns, with 2025 revenue growth now pegged to 8-14% at CER, down from previous forecasts.

Market CompetitionLilly's Mounjaro & Zepbound are expected to continue to take incremental U.S. share from Ozempic and Wegovy.

Sales ExpectationsLower Wegovy sales expectations were specifically impacted by continued/higher-than-expected compounding in the US market and slower-than-expected market expansion.

Novo Nordisk News

Bernstein upgrades Novo Nordisk with market ‘fully capitulated’

Bernstein analyst Florent Cespedes upgraded Novo Nordisk (NVO) to Outperform from Market Perform with a price target of...

8h ago

NVO

Novo Nordisk upgraded to Outperform from Market Perform at Bernstein

Bernstein upgraded Novo Nordisk (NVO) to Outperform from Market Perform. Published first on TheFly – the ultimate source...

8h ago

NVO

ICER update on GLP-1s a ‘win’ for Eli Lilly, says BofA

BofA notes that the Institute for Clinical and Economic Review released its updated draft report for obesity drugs...

9h ago

LLY

NVO

Hims Stock (HIMS) Rises as FDA Publishes “Green List,” Novo Nordisk Shares Slip

Hims & Hers ($HIMS) stock rose 2.6% on Monday after the U.S. Food and Drug Administration (FDA) released...

20h ago

LLY

NVO

Posse of U.S. Law Firms Saddles Up for Court Showdown with Novo Nordisk (NVO)

In healthcare, every mistake has a price—and a cohort of investors is sharpening its knives to send pharma...

2d ago

NVO

HIMS Stock Climbs 7% after Eli Lilly’s Knockoff Case Falls Flat

The stock of Hims & Hers Health Inc. ($HIMS) climbed nearly 7% on Wednesday after a court ruling...

5d ago

LLY

NVO

Quantum Software Stocks Surge as Real-World Deals and Revenue Potential Drive Investors’ Attention

Quantum computing has long focused on hardware and scalability, but now, as the technology becomes ever more promising...

6d ago

HON

IBM

Analyst Forecasts $25 Billion of Annual Sales for Eli Lilly’s (LLY) New Weight-Loss Pill

Management plans to seek approval for the new drug by year’s end. ...

7d ago

LLY

NVO

Moderately bullish activity in Novo Nordisk with shares down 0.76%

Moderately bullish activity in Novo Nordisk (NVO), with shares down 43c near $56.03. Options volume relatively light with...

7d ago

NVO

Chinese companies supplying ingredients for weight loss drugs, Reuters reports

Some Chinese companies looking to make generic versions of Novo Nordisk’s (NVO) Wegovy also supplied ingredients for more...

7d ago

LLY

NVO

Novo Nordisk Stock Jumps and Eli Lilly Falls on Positive Wegovy Data

Shares of Novo Nordisk ($NVO) are up 1.6% in pre-market trading after the Danish drugmaker announced that its...

8d ago

LLY

NVO

Novo says Wegovy cut risk of heart attack, death by 57% compared to tirzepatide

Novo Nordisk (NVO) presented data from the STEER real-world study of evidence gathered from actual patient experiences at...

8d ago

LLY

NVO

Eli Lilly (LLY) Rival Novo Nordisk’s Stock Pops in Europe on Wegovy Data

Danish drugmaker Novo Nordisk ($NVO), a top competitor to American pharmaceutical giant Eli Lilly ($LLY), is currently exciting...

8d ago

LLY

Bullish flow in Novo Nordisk with shares up 1.45%

Bullish flow in Novo Nordisk (NVO), with shares up 80c, or 1.45%, near $56.15. Options volume relatively light...

13d ago

NVO

NOVA FAQ

What was Novo Nordisk’s price range in the past 12 months?

Novo Nordisk lowest stock price was €38.20 and its highest was €124.50 in the past 12 months.

What is Novo Nordisk’s market cap?

Novo Nordisk’s market cap is $208.09B.

When is Novo Nordisk’s upcoming earnings report date?

Novo Nordisk’s upcoming earnings report date is Nov 05, 2025 which is in 57 days.

How were Novo Nordisk’s earnings last quarter?

Novo Nordisk released its earnings results on Aug 06, 2025. The company reported €0.789 earnings per share for the quarter, beating the consensus estimate of €0.782 by €0.007.

Is Novo Nordisk overvalued?

According to Wall Street analysts Novo Nordisk’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Novo Nordisk pay dividends?

Novo Nordisk does not currently pay dividends.

What is Novo Nordisk’s EPS estimate?

Novo Nordisk’s EPS estimate is 0.8.

How many shares outstanding does Novo Nordisk have?

Novo Nordisk has 3,390,128,000 shares outstanding.

What happened to Novo Nordisk’s price movement after its last earnings report?

Novo Nordisk reported an EPS of €0.789 in its last earnings report, beating expectations of €0.782. Following the earnings report the stock price went down -4.443%.

Which hedge fund is a major shareholder of Novo Nordisk?

Currently, no hedge funds are holding shares in DE:NOVA

Novo Nordisk Stock Smart Score

Neutral

Fundamentals

Return on Equity

75.95%

Trailing 12-Months

Asset Growth

42.90%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk (NOVA) Earnings & Revenues

Historic Earnings Reports

NOVA Company Deck

NOVA Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

Novo Nordisk reported strong sales and profit growth in the first half of 2025, with significant expansion in obesity care and international operations. However, the company lowered its full-year outlook due to challenges in the U.S. market and decreased free cash flow, reflecting both positive achievements and areas of concern.View all DE:NOVA earnings summaries

NOVA Stock 12 Month Forecast

Average Price Target

€57.81

▲(25.39% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"40":"€40","81":"€81","122":"€122","60.5":"€60.5","101.5":"€101.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":76.8357333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€76.84</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":57.8060833527,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€57.81</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42.6865185,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€42.69</span>\n  </div></div>","useHTML":true}}],"tickPositions":[40,60.5,81,101.5,122],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.1,51.233517946153846,53.3670358923077,55.50055383846154,57.63407178461539,59.76758973076923,61.901107676923075,64.03462562307692,66.16814356923078,68.30166151538461,70.43517946153847,72.56869740769231,74.70221535384616,{"y":76.8357333,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.1,49.769698719438466,50.439397438876924,51.10909615831539,51.778794877753846,52.44849359719231,53.11819231663077,53.78789103606923,54.45758975550769,55.127288474946155,55.79698719438461,56.46668591382308,57.13638463326154,{"y":57.8060833527,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.1,48.60665526923077,48.11331053846154,47.61996580769231,47.12662107692308,46.63327634615385,46.13993161538461,45.64658688461538,45.15324215384615,44.65989742307692,44.16655269230769,43.67320796153846,43.17986323076923,{"y":42.6865185,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":121.545,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.901,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.471,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.451,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.553,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.788,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.885,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.103,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.738,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.333,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.567,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.1,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >